DNTH-103 is under clinical development by Dianthus Therapeutics and currently in Phase I for Multifocal Motor Neuropathy. According to GlobalData, Phase I drugs for Multifocal Motor Neuropathy have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DNTH-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DNTH-103 overview

DNTH-103 is under development for the treatment of myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy. The drug candidate is a monoclonal antibody which is developed based on half-life extension technology. It acts by targeting complement C1s subcomponent. It is administered through intravenous and subcutaneous route.

Dianthus Therapeutics overview

Dianthus Therapeutics, formerly Magenta Therapeutic Inc, is a clinical-stage biotechnology company that develops and designs monoclonal antibodies. The company focuses on therapies to treat severe autoimmune and inflammatory diseases. Its lead drug candidate DNTH103, a long-acting monoclonal antibody for the treatment of generalized myasthenia gravis (gMG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP). Dianthus Therapeutics is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of DNTH-103’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.